Gilead gets subpoena from HHS over Ranexa

08/17/2009 | Boston Globe (tiered subscription model), The

The HHS issued a subpoena to Gilead Sciences asking for documents regarding the development, marketing and sales of Ranexa, a chronic angina drug developed by the Gilead-acquired firm CV Therapeutics. A company spokeswoman did not provide further information about the subpoena.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA